Copy Link Print Information

SB 202190

141 Cited Publications
カスタマーレビュー

Based on 141 publication(s) in Google Scholar

SB 202190 is a selective p38 MAP kinase inhibitor with IC50s of 50 nM and 100 nM for p38α and p38β2, respectively. SB 202190 binds to the ATP pocket of the active recombinant human p38 kinase with a Kd of 38 nM. SB 202190 has anti-cancer activity and rescued memory deficits. SB202190 induces autophagy.

商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。

  • 純度: 99.89%
  • CAS 番号: 152121-30-7
  • 分子式: C20H14FN3O
  • 分子量:331.34
  • 保管条件:
    Powder   -20°C, 3 years , 4°C, 2 years ; In solvent   -80°C, 2 years , -20°C, 1 year
  • SB 202190 Chemical Structure
    SB 202190 構造式
  • Experimental Validation Results for SB 202190
  • Experimental Validation Results for SB 202190
  • Experimental Validation Results for SB 202190
  • Experimental Validation Results for SB 202190
  • Experimental Validation Results for SB 202190
  • Experimental Validation Results for SB 202190
  • Experimental Validation Results for SB 202190
  • Experimental Validation Results for SB 202190
  • Experimental Validation Results for SB 202190
  • Experimental Validation Results for SB 202190
  • Experimental Validation Results for SB 202190
  • Experimental Validation Results for SB 202190
CAS 番号: 152121-30-7
容量
価格（税別）
在庫状況
数量
Amount: USD 0.00
Please select quantity
or
or

* アイテムを追加する前、数量をご選択ください

To place orders, for customer services and technical support, please contact: MedChemExpress USA

Tel: 609-228-6898 E-mail: [email protected] [email protected]

Data Download
Other Forms of SB 202190:

To place orders, for customer services and technical support, please contact:

609-228-6898
[email protected] [email protected]
最寄りの代理店をお探しください Your local distributor: Hycultec GmbHHycultec
  • 生物活性
  • 化学情報
  • 溶剤 & 溶解度
  • 純度とドキュメンテーション
  • 参考文献
  • Help & FAQs
You May Still Need
Top Publications Citing

Use of MCE Products

MedChemExpress（MCE）の使用を引用している文献 SB 202190

More
Customer Validation & Images
Cell Proliferation/Viability AssayWBRT-PCRIF
  • WB
  • Cell Proliferation/Viability Assay
  • IF
  • RT-PCR
  • WB
  • WB
  • RT-PCR
  • RT-PCR
  • WB
  • WB
  • WB
  • WB

p38 MAPK アイソフォーム固有の製品をすべて表示

More
Keywords
MOQ
Minimum order quantity
100 mg

お問い合わせ 在庫あり

Other size
お問い合わせ
Please select quantity
Amount: USD 0.00
Sign in to MedChemExpress ログイン
Register
Sign in to MedChemExpress
新規会員登録

At least 6 characters

Personalize your experience, you are currently not signed in. For a better experience, please create an online profile, you can:

Obtain points redemption prizes
Check out faster
Add multiple shipping locations
View orders
Assay Types
  • SB 202190 Chemical Structure
    SB 202190 Chemical Structure
    1/16
  • 1/16

    SB 202190 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Apr 7;16(1):3319. [Abstract]

    Customer Validation
     After treatment with 20 μM SB202190 for 2 h followed by heat stress for 1 h, KYSE 70 and KYSE150 cells were subjected to Western blot analysis.

  • 1/16

    SB 202190 purchased from MedChemExpress. Usage Cited in: NPJ Biofilms Microbiomes. 2024 Jan 20;10(1):5. [Abstract]

    Customer Validation
     Percentage cell proliferation of CT26 cells treated with MEK inhibitor U0126-EtOH (HY-12031; 25 µM), JNK inhibitor SP600125 (HY-12041; 25 µM), P38/MAPK inhibitor SB202190 (HY-10295; 20 µM), GSK3β inhibitor TWS119 (HY-10590; 20 µM), or AR-A014418 (HY-10512; 20 µM), and vehicle or Cori.ST1911. Cell OD was measured using the CCK8 method and normalised to cell proliferation of the control. Inhibitor treatment started 4 h before Cori.ST1911 treatment. Data are represented as mean ± SEM (n = 3 independent tests), analysed by one-way analysis of variance (ANOVA) with Bonferroni’s post-hoc test. n.s., no significance.

  • 1/16

    SB 202190 purchased from MedChemExpress. Usage Cited in: Mol Cancer. 2023 Jan 24;22(1):17. [Abstract]

    Customer Validation
     Representative images (top and middle rows) of organoids cultured for 3d in basic media with/without addition of FGF2 or the indicated inhibitors. Bottom row: Immunofluorescence staining of the frozen section of the organoids. U0126 (10 μM), PD184352 (1 μM), cytochalasin D (1 μM) and SB202190 (10 μM).

  • 1/16

    SB 202190 purchased from MedChemExpress. Usage Cited in: Nat Metab. 2023 Mar;5(3):481-494. [Abstract]

    Customer Validation
     Mt2gene expression in beige adipocytes treated with indicated compounds (50 ng/mL TNF, 2 μM BMS345541, 1 μM SCH772984, 5 μM SB202190 and 5 μM SP600125; n = 4 biological independent samples).

  • 1/16

    SB 202190 purchased from MedChemExpress. Usage Cited in: Acta Biochim Biophys Sin (Shanghai). 2019 Apr 1;51(4):365-374. [Abstract]

    Customer Validation
     MAPKs inhibitors suppress LPS-induced COX-2 expression and AKT1 phosphorylation. RAW264.7 cells are pretreated for 1 h with U0126, SB202190, SP600125 alone, or all the three inhibitors, respectively, and then exposed to 40 ng/ml LPS for 30 min or 12 h. The phosphorylated protein kinases and COX-2 expression are detected by western blot analysis using their corresponding antibodies.

  • 1/16

    SB 202190 purchased from MedChemExpress. Usage Cited in: J Cell Biochem. 2019 Mar;120(3):3898-3910. [Abstract]

    Customer Validation
     Cells pretreated with SP600125 show a decreased proapoptotic Bax expression and increase antiapoptotic Bcl-2 formation when JNK pathway is blocked. Inhibition of p38 by SB202190 significantly enhanced Bcl-2 expression. Pretreatment with BAY 11-7082 to inhibit NF‐κB markedly enhance Baxm and decrease Bcl-2 expression compared with the ACR-treated group.

  • 1/16

    SB 202190 purchased from MedChemExpress. Usage Cited in: J Neuroinflammation. 2018 Oct 19;15(1):291. [Abstract]

    Customer Validation
     Blocking the three MAPK signaling pathways through specific inhibitors (U0126; SB202190; and SP600125) significantly decrease the infection-induced neuroinflammatory response via real-time PCR analysis.

  • 1/16

    SB 202190 purchased from MedChemExpress. Usage Cited in: J Neuroinflammation. 2018 Oct 19;15(1):291. [Abstract]

    Customer Validation
     Blocking the three MAPK signaling pathways through specific inhibitors (U0126; SB202190; and SP600125) significantly decrease the infection-induced neuroinflammatory response via real-time PCR analysis.

  • 1/16

    SB 202190 purchased from MedChemExpress. Usage Cited in: Int J Mol Med. 2017 Jan;39(1):71-80. [Abstract]

    Customer Validation
     Inhibition of p38 expression enhances the promoting effect of miR-214 on the adipocyte differentiation of bone marrow-derived mesenchymal stem cells (BMSCs) following the overexpression of miR-214. p-p38 protein expression decreases following treatment with p38 inhibitor, as shown by (A) western blot analysis, and (B) statistical analysis of p-p38 protein expression.

  • 1/16

    SB 202190 purchased from MedChemExpress. Usage Cited in: Oxid Med Cell Longev. 2017:2017:7426458. [Abstract]

    Customer Validation
     Representative immunoblot analysis of p53, p16, p21, and retinoblastoma protein (Rb) in NP cells.

  • 1/16

    SB 202190 purchased from MedChemExpress. Usage Cited in: China Biotechnology. 2017, 37(12): 40-48.

    Customer Validation
     The Western blot analysis of HOG1 and Phospho-HOG1.

  • 1/16

    SB 202190 purchased from MedChemExpress. Usage Cited in: EBioMedicine. 2015 Nov 19;2(12):1944-56. [Abstract]

    Customer Validation
     SW620 xenograft tumors are treated with SB202190 and OSI027 individually or in combination. The effect on signaling by p38 (P-MK2 and P-Hsp27) and mTOR (P-S6K1 and P-AKT) is analyzed by immunoblot. SB202190 achieves on-target inhibition by diminishes phosphorylation of MK2 and Hsp27. OSI-027 blocks signaling by both mTORC1 and mTORC2 by decreases phosphorylation of S6K1 and AKT. When SB202190 and OSI-027 are used in combination, all three kinases, p38, mTORC1 and mTORC2 are potently inhibited.

  • SB 202190